Transgene SA (0OCQ.L)
| Previous close | 1.3520 |
| Open | 1.3520 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.3600 - 1.3600 |
| 52-week range | 1.3600 - 1.3600 |
| Volume | 9,010 |
| Avg. volume | N/A |
| Market cap | 189.616M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0650 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Is Transgene (EPA:TNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Simply Wall St.
Is Transgene SA's (EPA:TNG) ROE Of 35% Impressive?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Business Wire
Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, a therapeutic vaccine based on the myvac™ technology and powered by NEC’s cutting-edge AI capabilities. In these Phase 1 trials, TG4050 is being administered to patients with head and neck cancer who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy. Transgene’s highly innovative myvac™ technology allows the generation of a virus-based immunotherapy within a very short time frame while encoding patient-specific mutations identified and selected by NEC’s Neoantigen Prediction System.
